Fresenius Medical Care executes share buyback amid lowered profit forecast

Fresenius Medical Care AG is conducting a share buyback program, having acquired 1,010,540 shares between September 7 and September 11, 2026. This brings the total number of shares acquired within the first tranche of the program to 8,774,975. The transactions were executed through a commissioned credit institution on the Xetra and Cboe Europe exchanges.

Despite the buyback activity, the company's stock has faced downward pressure. As of September 16, 2026, the share price was trading near 39.70 EUR, remaining just below the 40 EUR mark. This movement follows a downward revision of the company's profit forecast for the current fiscal year. While technical analysis indicates a negative medium-term trend and relative underperformance compared to the STOXX 600 index, some fundamental analyses suggest the stock may be undervalued.